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Abstract 
Context: Phosphodiesterase-5 inhibitors (PDE5is) are prescribed off-label for the treatment of 
premature ejaculation (PE).   
Objective: To systematically review the evidence from randomised controlled trials (RCTs) for 
PDE5is in the management of PE. 
Evidence acquisition: MEDLINE and other databases were searched to September 2015. Quality of 
RCTs was assessed. Intra-vaginal ejaculatory latency time (IELT) data were pooled in a meta-
analysis. Heterogeneity was assessed.  
Evidence synthesis: Fifteen RCTs were included. The majority were of unclear methodological 
quality. Pooled IELT evidence suggests: PDE5is are significantly more effective than placebo (231 
participants, p<0.00001); there is no difference between PDE5is and selective serotonin reuptake 
inhibitors (SSRIs) (405 participants, p=0.50); and that PDE5is combined with an SSRI are 
significantly more effective than SSRIs alone (521 participants, p=0.001).  However, high levels of 
statistical heterogeneity are evident (I
2≥40%).  Single RCT evidence suggests that sildenafil is 
significantly more effective than the squeeze technique; but both lidocaine gel and tramadol are 
significantly more effective than sildenafil.  Sildenafil combined with behavioural therapy is 
significantly more effective than behavioural therapy alone.  Sexual satisfaction and ejaculatory 
control appear better with PDE5is compared with placebo and with PDE5is combined with an SSRI 
compared with an SSRI alone.  Adverse events are reported with both PDE5is and other agents.   
Conclusions: PDE5is are significantly more effective than placebo and PDE5is combined with an 
SSRI are significantly more effective than SSRIs alone at increasing IELT and improvement in other 
effectiveness outcomes.  However, heterogeneity is evident across RCTs.  The methodological quality 
of the majority of RCTs is unclear. 
Patient summary: We reviewed PDE5is for treating premature ejaculation.  We found evidence to 
suggest that PDE5is are effective compared with placebo and that PDE5is combined with an SSRI are 
better than an SSRI alone.  Adverse events are reported with PDE5is and other agents.  However, the 
quality of the evidence is uncertain. 
PROSPERO registration number: CRD42013005289  
1. Introduction 
Premature ejaculation (PE) is commonly defined by a short ejaculatory latency, a perceived lack of 
ejaculatory control; both related to self-efficacy; and distress and interpersonal difficulty [1].  PE can 
be either lifelong (primary - present since first sexual experiences), or acquired (secondary - 
beginning later) [2].  The International Society of Sexual Medicine’s Ad Hoc Committee for the 
Definition of Premature Ejaculation defines PE as a male sexual dysfunction characterised by 
ejaculation within about one minute of vaginal penetration (lifelong PE) or a clinically significant and 
bothersome reduction in latency time to ≤3 minutes (secondary PE), the inability to delay ejaculation, 
and negative personal consequences[3].   
The treatment of PE should attempt to alleviate concern about the condition as well as increase sexual 
satisfaction for the patient and the partner [4].  Available treatment pathways for the condition are 
varied and treatments may include both behavioural and/or pharmacological interventions.  
Phosphodiesterase-5 (PDE5) inhibitors are prescribed for the condition off-label.  A number of 
randomised controlled trials (RCTs) and observational studies have compared PDE5 inhibitors 
(PDE5is) with placebo, no therapy, behavioural therapy or pharmacological agents.  Previous reviews 
have summarised this evidence [5-9].  However, none to-date has presented a meta-analysis of only 
RCT evidence. 
The aim of this study was to systematically review the evidence for PDE5is, in the treatment of PE, 
by summarising evidence from RCTs and present a meta-analysis of treatment effectiveness. 
2. Evidence acquisition 
The review was undertaken in accordance with the general principles recommended in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
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2.1. Searches 
MEDLINE and other bibliographic databases were searched from inception to 30 September 
2015Details of all sources searched and full search terms are reported elsewhere [10].  All citations 
were imported into Reference Manager Software (version 12, Thomson ResearchSoft, Carlsbad, CA, 
USA) and any duplicates deleted.   
2.2. Eligible studies 
RCTs in adult men with PE that evaluated a PDE5i alone or in combination with another therapy were 
eligible for inclusion.  Single-arm randomised crossover design studies (participants randomised to 
different intervention periods) were excluded to avoid double counting of participants in the meta-
analysis.  Theses and dissertations were not included.  Non-English publications were included where 
sufficient data could be extracted from an English-language abstract or tables.   
The primary outcome was intra-vaginal ejaculatory latency time (IELT).  Other outcomes included 
sexual satisfaction, control over ejaculation, relationship satisfaction, self-esteem, quality of life, 
treatment acceptability and adverse events.   
2.3. Data extraction, quality assessment and data synthesis 
One reviewer performed data extraction of each included study.  All numerical data were then 
checked by a second reviewer.   
Methodological quality of RCTs was assessed using the Cochrane Collaboration risk of bias 
assessment criteria [11].  We classified RCTs as being at overall ‘low’ or ‘high’ risk of bias if they 
were rated as such for all three of the following key domains – (i) allocation concealment; (ii) 
blinding of outcome assessment; and (iii) completeness of outcome data (attrition <30%).   
Where possible, between-group differences were pooled across RCTs in a meta-analysis using 
Cochrane RevMan software (version 5.2) (RevMan 2012[12]).  Random-effects models were applied 
where I² value was >40%.  Between-group effect estimates were considered significant at p<0.05.  
Assessment of publication bias assessed by visual inspection of funnel plots was planned where ≥10 
RCT comparisons were available. 
3. Evidence synthesis 
3.1. Search results  
The searches identified 2,391 citations.  Of these, 2,369 citations were excluded as titles/abstracts.  
Twenty-two full-text articles were obtained as potentially relevant.  The study selection process is 
fully detailed in the PRISMA flow diagram in Supplementary Figure 1.  A total of 15 RCTs that 
evaluated a PDE5i (with or without a combined therapy) against a comparator were included. 
Details of the included RCTs are presented in Table 1. 
3.2. Risk of bias assessment of RCTs 
The majority of RCTs were considered at unclear risk of bias mainly due to lack of reporting of 
information to inform the risk of bias assessment.  Four RCTs were described as single-blind or open-
label and were considered at high risk of performance bias.[14-17]  One RCT was considered at high 
risk of selective reporting as although IELT and secondary outcomes were assessed, IELT outcomes 
were not reported and secondary outcomes minimally reported (no data)[14].  One RCT was 
considered to be at overall high risk of bias as group allocation sequence was according to patients’ 
presentation at clinic[17].  One RCT was considered to be at overall high risk of bias as numbers 
withdrawing at six months were imbalanced, with >30% in one group and no indication whether these 
participants were included in the analysis or otherwise[16].  We were unable to assess fully two RCTs 
fully as the body text was in Chinese-language, which were judged at overall unclear risk [18;19].  
Only one RCT was judged at overall low risk of bias [20].  A summary of the risk of bias assessment 
for each included RCT is presented in Supplementary Figure 2.  
3.3. Characteristic of RCTs  
Where reported, the definition of PE was varied and was defined according to: DSM-IV (Diagnostic 
and Statistical Manual of Mental Disorders) criteria[20-23], an IELT of two minutes or less 
[16;19;23;24], 1.5 minutes or less [22], or 1 minute or less [25;26]; a score of four or less on the 
CMASH (Center for Marital and Sexual Health questionnaire)[15], or was not reported 
[6;14;18;19;27].  The majority of RCTs recruited samples comprising men with lifelong PE and 
without erectile dysfunction.  One RCT recruited men with both lifelong and acquired PE[19] and one 
RCT recruited only me with acquired PE.[17]  The remaining RCTs recruited samples comprising 
men with lifelong PE.  Where reported, men with erectile dysfunction (ED) were excluded.  Where 
reported, ED was assessed by the majority of trials using the International Index of Erectile Function 
(IIEF).  IIEF ED cut-off scores for exclusion ranged from <21 to <26. 
The majority of RCTs evaluated sildenafil. [16-19;21;23-25]  Other PDE5is included 
tadalafil,[14;22;26;27] mirodenafil[20] and vardenafil[15;28].  With the exception of one RCT 
prescribing tadalafil twice weekly[14], all RCTs prescribed PDE5is prior to sexual intercourse.  
Comparators included placebo, selective serotonin re-uptake inhibitors (SSRIs), tramadol, behavioural 
therapy, and anaesthetic gels or creams.  With the exception of three RCTs prescribing an SSRI 
daily[14;16;17;26] or weekly[22]; and one RCT prescribing a daily SSRI for four weeks followed 
initially followed by administration on demand prior to sexual intercourse to week 16[25]; SSRIs 
were prescribed to be taken prior to sexual intercourse, including one RCT prescribing dapoxetine 
(approved administration on-demand for the treatment of PE[29]) [20].  Five RCTs evaluated 
combination therapies comprising PDE5is combined with an SSRI.[14;17;20;22;25] Treatment 
duration ranged from four weeks to six months.  Where reported, trials were undertaken in both EU 
and non-EU countries. 
3.4. Outcome data reported in RCTs 
With the exception of one RCT reporting ‘improvement’ or ‘cure’[21], all RCTs reported IELT 
outcomes as a time metric.  One RCT assessed IELT using a visual scale of ejaculatory latency time 
questionnaire, although no outcome data were reported[14].  Two RCTs reported that IELT was 
estimated by patients without using a stopwatch.[17;27]  The remaining RCTs reported that IELT was 
assessed using a stopwatch. 
The reporting of other efficacy outcomes was varied, both in the assessment method (Table 1) and the 
outcome data available (Supplementary Table).  The outcome data for adverse event (AE) reporting 
was similarly disparate in terms of the types of adverse events and whether the proportion was the 
number of patients or the number of AEs (Table 2, Supplementary Table).   
3.5. IELT outcomes 
A results summary of the effectiveness outcomes and adverse events is presented in Table 2. 
IELT - PDE5is vs. placebo:  The pooled effect estimate across three RCTs[22-24] (231 participants) 
(I
2
=42%, random-effects) was 2.21 minutes (95% CI 1.45 to 2.97; p<0.00001) in favour of PDE5is 
(Figure 1, Table 2).  The between-group difference in geometric mean increase in IELT from one 
additional RCT [28] (40 participants) was 3.60 minutes in favour of vardenafil compared with placebo 
[MD (fixed effect) 95% CI, 3.10 to 4.10; p<0.00001].   
IELT - PDE5is vs. SSRIs:  Pooled effects across six RCTs[15;16;18;22;24;27] (405 participants) for 
PDE5is compared with SSRIs display high levels of between-trial heterogeneity (I
2
=95%).  The 
pooled between-group difference in IELT was 0.33 minutes (random-effects; 95%CI, -0.63 to 1.30; 
p=0.50) (Figure 2, Table 2).   
IELT - PDE5is plus SSRIs vs. SSRIs:  Pooled effects across six RCTs[17;19;20;22;25;27] (521 
participants) for PDE5is plus SSRI combination therapy compared with SSRIs alone display high 
levels of between-trial heterogeneity (I
2
=75%).  The pooled between-group differences in IELT was 
1.52 minutes (random-effects; 95%CI, 0.98 to 2.05; p<0.00001) in favour of PDE5i/SSRI 
combination therapy (Figure 3, Table 2).  One further RCT reported a between-group difference in 
change in IELT at 6 weeks of 1.02 minutes in favour of tadalafil plus sertraline compared sertraline 
plus placebo. [26]  Variance estimates were not reported.  The authors reported a p-value for the 
between-group difference of p=0.001. 
IELT - PDE5is vs. squeeze technique, lidocaine gel or tramadol:  Sildenafil was significantly more 
effective than the squeeze technique (one RCT, 120 participants [16]) at increasing IELT (MD 3.56 
minutes [95% CI 3.16 to 3.96; p<0.00001]) (Figure 4, Table 2).  Both lidocaine gel and tramadol (one 
RCT, [24] 60 and 59 participants respectively) were significantly more effective than sildenafil at four 
weeks (MD 0.83 minutes [95% CI 0.05 to 1.61; p=0.04]; and 2.04 minutes [95% CI 1.21 to 2.87], 
p<0.00001 respectively) (Figure 4). 
IELT - PDE5is plus behavioural therapy vs. behavioural therapy:  Sildenafil combined with 
behavioural therapy (not described) was significantly more effective than behavioural therapy alone 
(one RCT, 60 participants [18]) at increasing IELT (MD 3.56 minutes 1.81 minutes [95% CI 1.53 to 
2.09], p<0.00001) (figure not presented).   
3.6. Outcomes other than IELT 
The assessment and reporting of outcomes other than IELT was diverse across RCTs (Supplementary 
Table).  Where statistically significant between-group differences were reported, single RCT evidence 
indicated that: sexual satisfaction was significantly greater with a PDE5i compared with placebo, 
[23;24] as was ejaculatory control and ejaculatory confidence [23]; there were no statistically 
significant differences between PDE5is and SSRIs on PE Grade scores, [15;16] or IIEF [27]; whilst 
for PDE5is combined with an SSRI in comparison with an SSRI alone there was a significantly 
greater increase in the combined therapy group in intercourse satisfaction [19;25]; control over 
ejaculation, sexual act time and interpersonal difficulty related to ejaculation[20] and intercourse 
frequency [19]. (Table 2)  Sexual satisfaction was also significantly better with sildenafil compared 
with lidocaine gel, or tramadol[24]; and patient and partner sexual satisfaction was significantly better 
with sildenafil combined with behavioural therapy than behavioural therapy alone.[18] (Table 2). 
3.7. Safety outcomes 
Limitations in the reporting of adverse events did not permit a meta-analysis for this outcome 
(Supplementary table).  Single RCT evidence suggests that sildenafil and tadalafil and are associated 
with a greater incidence of flushing and headache compared with placebo [21-23] and tadalafil is also 
associated with a greater incidence of palpitations.[22;23] (Table 2).  Single RCT evidence also 
suggests that whilst differing in the type of some adverse events, both PDE5is and SSRIs are 
associated with adverse events (Table 2).  Single RCT evidence for PDE5is combined with an SSRI 
compared with SSRI alone also suggests that whilst differing in the type of some adverse events, both 
combination therapy and monotherapy are associated with adverse events; with more headache and 
flushing reported for: sildenafil plus fluoxetine compared with fluoxetine[25] and sildenafil plus 
sertraline compared with sertraline[17;19] (Table 2).  
4. Discussion 
Pooled evidence suggests that PDE5is are significantly more effective than placebo at increasing 
IELT over four to 12 weeks.  The two RCTs that evaluated sildenafil excluded men with erectile 
dysfunction defined as an International Index of Erectile Function score <22[23;24]  However, one of 
these RCTs reported that some of the patients enrolled may have had mild comorbid erectile 
dysfunction.[23]  One of the placebo-controlled RCTs was described as single-blind, which may have 
contributed to selection bias[24].  Allocation concealment was not reported by two of the RCTs, 
which may have also contributed to selection bias.[23;24]  Blinded outcome assessment was also not 
reported by these two RCTs, which may have contributed to detection bias.  Due to the clinical and 
observed statistical heterogeneity coupled with the limited methodological quality across RCTs, these 
results should be interpreted with caution. 
Sexual satisfaction, ejaculatory control and ejaculatory confidence appear significantly better with 
PDE5i than placebo.  However, more adverse events including headache and flushing appear to be 
reported with PDE5is compared with placebo. 
Pooled evidence suggests that there is no statistically significant difference in IELT between PDE5is 
and SSRIs over four to 24 weeks.  However, a high level of statistically significant between-trial 
heterogeneity is evident.  Across these RCTs, where reported the administration of the PDE5i was 30 
minutes, [15] one hour, [16;24]  two hours,[27] or one to three hours pre-coitus;[27]  two reporting 
that the time of administration was the same in both treatment groups (two hours). [27]  In terms of 
the SSRI comparator, one RCT reported that sertraline was prescribed four hours prior to sexual 
intercourse[15], whilst one RCT did not report the time of sertraline administration[18].  Paroxetine 
was prescribed two hours before intercourse [27], four hours before intercourse,[24] or daily [16].  
Fluoxetine was prescribed 90mg once per week. [22]  The half-lives of fluoxetine, paroxetine and 
sertraline range from 16 to 96 hours[30].  SSRIs such as these are absorbed relatively slowly, but 
completely, by the gut (time to peak plasma concentration is 4 to 6 hours)[31].  Current 
recommendations for SSRIs in the treatment of PE include dapoxetine on-demand (the only approved 
SSRI for treatment of PE) or other off-label daily SSRIs that are not amenable to on-demand.[32]  
The variability across the included RCTs in the present review in terms of dosage and time of 
administration of the SSRI comparator may account for some of the observed heterogeneity in IELT.   
No significant between-group differences are evident on either the PE Grade or the IIEF for PDE5is 
compared with SSRIs.  Adverse events are reported with both PDE5is (e.g., headache, palpitations 
and flushing) and SSRIs (e.g., somnolence, headache and nausea). 
Pooled evidence across six RCTs suggests that combination therapy comprising PDE5i plus an SSRI 
is significantly more effective at increasing IELT over eight to 16 weeks compared with an SSRI 
alone.  However, a high level of statistically significant between-trial heterogeneity is evident.  Across 
the RCTs included in this meta-analysis, the IELT results were diverse.  There was no statistically 
significant difference in IELT between tadalafil or tadalafil combined with fluoxetine taken weekly 
and fluoxetine weekly alone[22]  Similarly, there was no significant difference on IELT from one 
RCT between mirodenafil combined with dapoxetine on-demand and dapoxetine alone[20].  However, 
sildenafil combined with sertraline daily was significantly more effective at increasing IELT when 
compared with sertraline daily alone in men with both lifelong[19] and acquired PE[17].  Whilst there 
was no significant difference in IELT between tadalafil and paroxetine on-demand from one RCT 
(100 participants), evidence from the same RCT also suggests that tadalafil combined with paroxetine 
on-demand is significantly more effective on IELT than tadalafil alone [27].  In the RCT by Polat et 
al. [27] the study authors reported that they did not use a stopwatch to measure IELT in order to avoid 
any decrease in the quality of sexual intercourse.  They also compared their observations with those of 
a prospective study evaluating combination therapy of sildenafil and paroxetine on-demand on 
IELT[33], noting that the study reported a significant improvement in IELT in patients using 
combined therapy and that the patients under combined therapy reported significantly greater 
intercourse satisfaction than those receiving paroxetine alone.  However, Polat et al. [27] did not 
report on ejaculatory control or sexual satisfaction, noting this as a study limitation.  IELT is reported 
to have a significant direct effect on perceived control over ejaculation, but not a significant direct 
effect on ejaculation-related personal distress or satisfaction with sexual intercourse [34].   
Intercourse satisfaction and frequency; control over ejaculation, sexual act time and interpersonal 
difficulty appear significantly better with PDE5is combined with an SSRI compared with SSRI alone.  
Adverse events are reported with both PDE5 inhibitors combined with an SSRI and SSRI alone, with 
more headache and flushing associated with PDE5 inhibitors combined with an SSRI. 
Single RCT evidence suggests sildenafil is significantly more effective than the squeeze technique at 
increasing IELT[16] and that sildenafil combined with behavioural therapy is significantly more 
effective than behavioural therapy alone.[18]  Single RCT evidence also suggests that both lidocaine 
gel and tramadol on-demand are both significantly more effective than sildenafil at increasing 
IELT.[24]   However, the same RCT reported that the greatest improvement in sexual satisfaction was 
with sildenafil, which was significantly better than paroxetine or lidocaine gel.   
The risk of bias assessment undertaken for this review indicates the majority of RCTs evaluating 
PDE5is in the treatment of PE are of unclear risk of detection bias, mainly due to limited reporting 
regarding blinding of the outcome assessment.  Key aspects of best practice in RCT design to 
minimise bias include a robust randomisation method, concealment of treatment group allocation, 
and, where possible, blinding of participants and trial personnel, and blinded outcome assessment; all 
of which should be clearly stated in the RCT report [35].  The unclear methodological quality of the 
current evidence base for PDE5is in the treatment of PE, coupled with the limited reporting by some 
RCTs of the presence or otherwise of erectile dysfunction [14;19;26] supports existing concerns 
regarding limited well-designed studies that evaluate the use of PDE5is in PE patients without erectile 
dysfunction.[36] 
The strengths of the present review are that it was undertaken to high methodological standards.[37]  
Several electronic database sources were searched for evidence.  RCT evidence for mirodenafil, 
sildenafil, tadalafil, and vardenafil in the management of PE were identified.  No RCT evidence for 
avanafil or udenafil in PE was identified.  Study selection and data extraction was undertaken by two 
reviewers.  Methodological quality of included studies was assessed.  A meta-analysis was presented.  
Limitations include the following. Theses and dissertations were not included and non-English 
publications were not fully translated (only the English language abstract was used).  Although our 
database search strategy was comprehensive, the possibility of a publication bias cannot be 
discounted.  Insufficient numbers of RCT comparisons were available for any meaningful assessment 
of funnel plot symmetry to be undertaken.   
In the review by Asimakopoulos et al. (2012),[5] which included a meta-analysis for PDE5is 
compared with placebo and a meta-analysis of PDE5is combined with an SSRI compared with SSRI 
alone, the authors pooled IELT effect estimates across studies using a standardised mean difference.  
However, the method assumes that the differences in standard deviations among studies reflect 
differences in measurement scales and not real differences in variability among study populations.[38]  
The present review has presented a mean difference meta-analysis.  Asimakopoulos et al. (2012),[5] 
pooled data across different study types (non-randomised studies, laboratory ejaculatory latency time 
studies and RCTs) in the same meta-analysis.  The present review has meta-analysed only RCT 
evidence, including six additional RCTs[14;17;20;24;26;27] to those included in the Asimakopoulos 
et al. (2012) review [5].  The present review also presents a meta-analysis of IELT for PDE5is 
compared with SSRIs and summarises the RCT evidence for PDE5is compared with topical 
anaesthetics, tramadol and behavioural therapy. 
All mean IELT data used in the present review were those reported in the original RCT article.  Only 
one RCT reported IELT as a geometric mean (data not pooled with other RCTs).[28]  A positively 
skewed IELT distribution may overestimate treatment effects if the mean IELT, instead of the 
geometric mean IELT, is reported.[39]  As such, the IELT outcomes in the present review should be 
interpreted with caution. 
It is difficult to quantify how acceptable and meaningful the changes in IELT are for men with PE, 
without being able to evaluate the relationship between IELT, ejaculation control, and sexual 
satisfaction from the current RCT evidence.  IELT is reported to have a significant direct effect on 
perceived control over ejaculation, but not a significant direct effect on ejaculation-related personal 
distress or satisfaction with sexual intercourse [34].  There is currently no published literature which 
identifies a clinically significant threshold for IELT response to any intervention [40].  PDE5is might 
offer an acceptable treatment option for men with PE both as a means of a second attempt at 
intercourse and in terms of the adverse event profile compared with other pharmacological agents.  
However, the reporting of adverse events across the current evidence is disparate often with only 
selected adverse events reported or numbers of participants experiencing adverse events not reported 
by group which restricts statistical pooling across RCTs.  Furthermore, interaction effects between 
PDE5is and SSRIs are not presently evaluated in the RCT evidence base.  Patient acceptability or 
persistence with treatment are also not evaluated in the current RCT evidence base. 
5. Conclusions 
The present systematic review has evaluated the safety and efficacy of PDE5is in the treatment of 
premature ejaculation.  The possible mechanisms of the action of PDE5is, along with long-lasting 
effects and age-dependent efficacy were outside of the scope for the review as was change in erectile 
function.  Pooled RCT evidence suggests that PDE5is are significantly more effective than placebo 
and that PDE5is combined with an SSRI are significantly more effective than SSRI alone at 
increasing IELT in men with PE.  Increases in IELT are not significantly different between PDE5is 
compared with SSRIs.  However, these findings should be interpreted with caution given the high 
levels of statistically heterogeneity that are evident across RCTs and the clinical heterogeneity of 
recruited participants along with the unclear methodological quality of the existing RCT evidence 
base.  Furthermore, a potential bias in the evaluation of any interventions for treating PE is the effect 
of the relationship between clinician and patient.  Single RCT evidence suggests a PDE5i is 
significantly better than squeeze technique, but that both lidocaine gel and tramadol are significantly 
better than a PDE5i on IELT.  Single RCT evidence also suggests that a PDE5i combined with 
behavioural therapy is better on IELT than behavioural therapy alone.  We found no RCT evidence 
comparing PDE5is directly with psychotherapeutic techniques.  Other efficacy outcomes including 
sexual satisfaction and ejaculatory control appear better with PDE5is compared with placebo and with 
PDE5is combined with an SSRI compared with an SSRI alone.  Adverse events are reported with both 
PDE5is and with SSRIs. 
Further RCTs should be better reported in line with the CONSORT statement,[35] and should report 
on patient acceptability of PDE5is along with clearer reporting on adverse events in order to permit 
future pooling of data across RCTs.  Future studies should also evaluate the relationship between 
changes in IELT and other efficacy outcomes including sexual satisfaction and ejaculatory control.  
Long term follow-up of safety and efficacy outcomes and persistence with treatment are also 
warranted along with effects of treatment discontinuation 
6. Acknowledgements 
This work was funded by NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC).
References 
 (1)  McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I, Adaikan PG, Becher E, 
Broderick GA, Buvat J, Dabees K, Giraldi A, Giuliano F, Hellstrom WJG, Incrocci L, Laan 
E, Meuleman E, Perelman MA, Rosen R, Rowland D, Segraves R. An evidence-based 
definition of lifelong premature ejaculation: report of the International Society for Sexual 
Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int 2008; 
102:338-350. 
 (2)  Godpodinoff ML. Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther 
1989; 15:130-134. 
 (3)  Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, Becher EF, 
Dean J, Giuliano F, Hellstrom WJG, Giraldi A, Glina S, Incrocci L, Jannini E, McCabe M, 
Parish S, Rowland D, Segraves RT, Sharlip I, Torres LO. An Evidence-Based Unified 
Definition of Lifelong and Acquired Premature Ejaculation: Report of the Second 
International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature 
Ejaculation. Sexual Medicine 2014; 2:41-59. 
 (4)  Richardson D, Goldmeier D, Green J, Lamba H, Harris JRW. Recommendations for the 
management of premature ejaculation: BASHH Special Interest Group for Sexual 
Dysfunction. International Journal of STD and AIDS 2006; 17:1-6. 
 (5)  Asimakopoulos AD, Miano R, Finazzi Agro E, Vespasiani G, Spera E. Does current scientific 
and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment 
of premature ejaculation? a systematic review and meta-analysis. J Sex Med 2012; 9:2404-
2416. 
 (6)  Aversa A, Francomano D, Bruzziches R, Natali M, Spera G, Lenzi A. Is there a role for 
phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation? Int J Impot Res 
2011; 23:17-23. 
 (7)  Burton TD, Liday C. The comparison of combination SSRI and PDE-5 inhibitor therapy to 
SSRI monotherapy in men with premature ejaculation. Ann Pharmacother 2011; 45:1000-
1004. 
 (8)  Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The Role of Phosphodiesterase Type 5 
Inhibitors in the Management of Premature Ejaculation: A Critical Analysis of Basic Science 
and Clinical Data. Eur Urol 2007; 52:1331-1339. 
 (9)  McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 
phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic 
review. BJU Int 2006; 98:259-272. 
 (10)  Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A. Interventions to 
treat premature ejaculation: a systematic review short report. Health Technology Assessment 
2015; 19:1-180. 
 (11)  Higgins JPT, Altman DG, Sterne JAC, on behalf of the Cochrane Statistical Methods Group 
and the Cochrane Bias Methods Group. Assessing risk of bias in included studies. In Higgins 
JPT GS, editor.  Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 
(updated March 2011).  The Cochrane Collaboration.  Available from www.cochrane-
handbook.org. 2011. [Accessed 4 January 2016] 
 (12)  The Nordic Cochrane Centre TCC. The Cochrane Collaboration Review Manager (RevMan). 
[5.2]. 2012. [Accessed 4 January 2016] 
 (13)  Higgins JPTH, Thompson SG, Deeks JJ, Altman.D.G. Measuring inconsistency in meta-
analyses. BMJ 2003; 327:557-560. 
 (14)  Culha M, Ozkan L, Ozkurkcugil C, Gokalp A. Comparison of fluoxetine vs. fluoxetine plus 
tadalafil in the treatment of premature ejaculation - a double blind, placebo control study. J 
Sex Med 2008; 5:60-61. 
 (15)  Mathers MJ, Klotz T, Roth S, Lummen G, Sommer F. Safety and efficacy of vardenafil 
versus sertraline in the treatment of premature ejaculation: a randomised, prospective and 
crossover study. Andrologia 2009; 41:169-175. 
 (16)  Wang WF, Wang Y, Minhas S, Ralph DJ. Can sildenafil treat primary premature ejaculation? 
A prospective clinical study. Int J Urol 2007; 14:331-335. 
 (17)  Zhang X, Tang D, Yang J, Shi K, Goa J, Hao Z, Zhou J, Liang C. Combination of Sertraline 
and Sildenafil versus Sertraline Monotherapy in the Treatment of Acquired Premature 
Ejaculation without Concomitant Diseases. Andrology 2014. 
 (18)  Tang W, Ma L, Zhao L, Liu Y. Efficacy and safety of sertraline, viagra and cardura in 
patients with premature ejaculation. Chinese Journal of Andrology 2004; 18:20-2, 25. 
 (19)  Zhang XS, Wang YX, Huang XY, Leng J, Li Z, Han YF. Comparison between sildenafil plus 
sertraline and sertraline alone in the treatment of premature ejaculation. Zhonghua Nan Ke 
Xue 2005; 11:520-525. 
 (20)  Lee WK, Cho ST, Lee YS, Oh CY, Yu CH, Cho JS, Lee SK, Yang DY. Comparison between 
on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with 
premature ejaculation; prospective, randomized, doubleblind, and placebo-controlled. J Sex 
Med 2012; 9:203-204. 
 (21)  Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U. Comparison of efficacy of 
sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in 
treatment of premature ejaculation. Urology 2006; 67:388-391. 
 (22)  Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: 
prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008; 80:162-165. 
 (23)  McMahon CG, Stuckey BGA, Andersen M, Purvis K, Koppiker N, Haughie S, Boolell M. 
Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005; 
2:368-375. 
 (24)  Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy AE-
N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the 
management of premature ejaculation: A randomised placebo-controlled clinical trial. Arab J 
Urol 2013; 11:392-397. 
 (25)  Hosseini MM, Yarmohammadi H. Effect of fluoxetine alone and in combination with 
sildenafil in patients with premature ejaculation. Urol Int 2007; 79:28-32. 
 (26)  Mokhtari G, Damavand RS, Khosropanah I, Roushani A, Kazemnezhad E, Esmaeili S, 
Baghani H, Motiee R. The efficacy and safety of combination therapy with tadalafil and 
serteraline in lifelong premature ejaculation: A randomized double blind study using a 
validated questionnaire. International Journal of Urology 2014; 21, A274. 2014. 
 (27)  Polat EC, Ozbek E, Otunctemur A, Ozcan L, Simsek A. Combination therapy with selective 
serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature 
ejaculation. Andrologia 2014;n/a. 
 (28)  Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G, Spera G. Effects of 
vardenafil administration on intravaginal ejaculatory latency time in men with lifelong 
premature ejaculation. Int J Impot Res 2009; 21:221-227. 
 (29)  European Medicines Agency. Questions and answers on Priligy (dapoxetine, 30 mg and 60 
mg tablets). Outcome of a procedure under Article 29 of Directive 2001/83/EC as amended. 
20 January 2012. EMA/CHMP/842278/2011 Rev. 1. EMEA/H/A-29/1294. European 
Medicines Agency . 20-1-2012. 8-7-2013.  
 (30)  Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. 
Pharmacology & Therapeutics 2000; 85:11-28. 
 (31)  van Harten J. Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors. Clin 
Pharmacokinet 1993; 24:203-220. 
 (32)  Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y, 
Wespes E. Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature 
ejaculation. European Association of Urology. 2015.  European Association of Urology.  
 (33)  Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, Guazzoni G, Rigatti P, 
Montorsi F. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil 
in patients with premature ejaculation. The Journal of urology 2002; 168:2486-2489.  
 (34)  Patrick DL, Rowland D, Rothman M. Interrelationships among measures of premature 
ejaculation: the central role of perceived control. The journal of sexual medicine 2007; 4:780-
788.  
 (35)  Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for 
reporting parallel group randomised trials. BMJ 2010; 340;c322 
 (36) Jannini EA, McMahon C, Chen J, Aversa A, Perelman M. The controversial role of 
phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation. J Sex Med 
2011; 8:2135-2143. 
 (37)  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 
6:e1000097. 
 (38)  Deeks JJ, Higgins JPT, Altman D.G.on behalf of the Cochrane Statistical Methods Group. 
Chapter 9:  Analysing data and undertaking meta-analyses. In Higgins JPT, Green S, editors. 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 
2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org., 
2011. [Accessed 4 January 2016] 
 (39)  Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Geometric mean IELT and 
premature ejaculation: Appropriate statistics to avoid overestimation of treatment efficacy. 
Journal of Sexual Medicine 2008; 5:492-499. 2008.  
 (40)  McMahon CG. Clinical trial methodology in premature ejaculation observational, 
interventional, and treatment preference studies--part II--study design, outcome measures, 
data analysis, and reporting. J Sex Med 2008; 5:1817-1833. 
  
Table 1. RCT study details, source of study, treatments and outcomes 
PDE5 inhibitor monotherapy RCTs 
Author (country) 
 
Duration 
PE definition/IELT 
Lifelong/acquired PE 
Erectile dysfunction 
PDE5i group, n randomised Comparator group(s), n randomised Outcomes 
Atan 2006 [21] 
(Turkey) 
 
8 weeks 
DSM-IV 
Lifelong and acquired PE 
ED, IIEF ED <21 excluded 
Sildenafil 50 mg 45 min PC, 20 
 
Sildenafil 50 mg 45 min PC + topical 
EMLA 15 min PC, 15 
Topical EMLA 15 min PC, 22 
Placebo, 20 
Ejaculation delay - “no 
change,” “improvement,” or 
“cure” according to patient 
self-report 
Adverse events 
Aversa 2009[28] 
(Italy) 
 
8 weeks 
PE/IELT, NR 
All lifelong PE 
ED, IIEF ED <22 excluded 
Vardenafil 10mg 15-30 min PC, 31 
 
Placebo 15-30 min PC, 11 IELT - Stopwatch  
Index of Premature 
Ejaculation (IPE)  
Adverse events 
Gameel 2013 [24] 
(Egypt) 
 
4 weeks 
IELT of <2 min in >75% 
of episodes 
All had PE for >1 year  
ED, IIEF ED <22 excluded 
Sildenafil 50mg 1h PC + inert 
lubricating gel 15min PC, 30 
 
Paroxetine 20mg 4h PC + inert lubricating 
gel 15min PC, 30 
Tramadol 50mg 2h PC + inert lubricating 
gel 15min PC, 30 
Lidocaine gel 15min PC + oral 
multivitamin 1-4h PC, 30 
Placebo (oral multivitamin 1-4h PC +inert 
lubricating gel 15min PC), 30 
IELT - stopwatch 
Sexual satisfaction - 0 to 5 
point scale 
Adverse events 
Mathers 2009 [15] 
(Germany) 
 
6 weeks 
CMASH score, ≤4  
All lifelong PE 
ED, IIEF ED <25 excluded 
Vardenafil 10mg 30min PC, 26 
 
Sertraline 50mg 4 h PC, 23 IELT - stopwatch 
Premature Ejaculation grade 
(PE Grade) 
Adverse events 
 
McMahon 2005[23] 
(Australia and 
Norway) 
 
8 weeks 
DSM-IV, IELT ≤ 2 min 
All lifelong PE 
ED, IIEF ED <22 excluded 
Sildenafil 50 to 100 mg 1 h PC, 73 
 
Placebo, 71 IELT - Stopwatch  
Index of Premature 
Ejaculation (IPE)  
Adverse events 
Tang 2004 [18] 
(China) 
 
6 weeks 
PE def, NR 
Lifelong/acquired, NR 
ED, excluded – criteria NR 
Sildenafil 50mg + behavioural therapy, 
30 
 
Behavioural therapy, 30 
Sertraline (dose NR) + BT, 30 
IELT - Stopwatch  
Patient/partner sexual 
satisfaction - 0 to 5 point 
Likert 
Wang 2007 [16] 
(China) 
 
12 and 24 weeks 
IELT ≤ 2 min 
All lifelong PE 
ED, IIEF ED <22 excluded 
Sildenafil 50mg 1 h PC, 60 
 
Paroxetine 20mg/d, 60 
Squeeze technique, 60 
IELT - Stopwatch  
Premature Ejaculation grade, 
intercourse satisfactory score, 
frequency of intercourse 
Adverse events 
PDE5 inhibitor combined with SSRI RCTs 
Author (country) 
 
Duration 
PE definition/IELT 
Lifelong/acquired PE 
Erectile dysfunction 
PDE5i plus SSRI group, n 
randomised 
Comparator group(s), n randomised Outcomes 
Culha 2008 [14] 
(Turkey) 
 
10 weeks 
PE/IELT, NR 
Lifelong/acquired, NR 
ED, NR 
Tadalafil 20 mg twice weekly + 
fluoxetine 20 mg per day 
 
Fluoxetine 20 mg per day 
Placebo 
Total n, 180 
IELT - Visual scale of 
ejaculatory latency time 
questionnaire (ELTQ) 
Adverse events 
Hosseini 2007[25] 
(Iran) 
 
16 weeks 
 
IELT ≤1 min 
All lifelong PE 
ED, IIEF excluded, cut-off 
score NR 
Sildenafil 50 mg 1 h PC + fluoxetine 20 
mg 2-3 h PC, 50 
 
Fluoxetine 10 mg twice daily for 4 weeks 
then 20 mg 2-3 h PC, 50 
IELT - stopwatch 
Intercourse satisfaction  - 
instrument not reported 
Adverse events 
Lee 2012[20] 
(Korea) 
 
12 weeks 
DSM-IV 
All lifelong PE 
ED, IIEF ED <22 excluded 
Mirodenafil 50 mg + dapoxetine 30 
mg, 1-3 h PC, 63 
 
Dapoxetine 30 mg + placebo, 1-3 h PC, 57 IELT - stopwatch 
Time from foreplay to 
beginning intercourse (FTIT) 
Overall sexual act time 
(OSAT) 
Premature Ejaculation Profile 
(PEP) 
Adverse events 
Mokhtari 2014[26] 
(Country NR) 
 
6 weeks 
PE def, NR, IELT ≤ 1.0 
min 
All lifelong PE 
ED NR 
Tadalafil 10mg PC + sertraline 50mg/d, 
56 
 
Sertraline 50mg/d + placebo PC, 52 IELT - Stopwatch  
Adverse events 
Zhang 2005 [19] 
(China) 
 
12 weeks 
PE def, NR 
Lifelong and acquire PE 
ED, NR 
Sildenafil 50 mg 1 h PC + sertraline 50 
mg/d 
 
Sertraline 50 mg/d 
Total n=72 
IELT - Stopwatch  
International Index of Erectile 
Function (IIEF) 
Adverse events 
Zhang 2014[17] 
(China) 
 
4 and 8 weeks 
IELT ≤ 2 min 
All acquired PE 
ED, IIEF ED <22 excluded 
Sildenafil 50mg 30min PC +sertraline 
50mg/d, 60 
 
Sertraline 50mg/d, 60 IELT - estimated by patients 
without stopwatch 
 
Premature Ejaculation Profile 
(PEP) 
Clinical Global Impression of 
Change (CGIC) 
Adverse events 
RCTs evaluating PDE5 inhibitor alone and in combination with an SSRI 
Author (country) 
 
Duration 
PE definition/IELT 
Lifelong/acquired PE 
Erectile dysfunction 
PDE5i group, n randomised 
PDE5i plus SSRI group, n 
randomised 
Comparator group(s), n randomised Outcomes 
Mattos 2008[22] 
(Brazil) 
 
12 weeks 
DSM-IV, IELT ≤ 1.5 min 
All lifelong PE 
ED, IIEF ED <26 
Tadalafil 20 mg 1-3 h PC, 15 
Tadalafil + fluoxetine, 15 
 
Fluoxetine 90 mg weekly, 15 
Placebo, 15 
IELT - stopwatch 
Adverse events 
 
Polat 2014[27] 
(Turkey) 
 
4 and 12 weeks 
PE def, NR 
All lifelong PE 
ED, excluded – criteria NR 
Tadalafil 20mg 2 h PC, 50 
Tadalafil + paroxetine, 50 
Paroxetine 20mg 2 h PC, 50 
 
IELT - estimated by patients 
without stopwatch 
International Index of Erectile 
Function (IIEF)  
Adverse events 
BT, behavioural therapy; CGIC, Clinical Global Impression of Change; CMASH, Center for Marital and Sexual Health; def., definition; DSM, Diagnostic and Statistical 
Manual of Mental Disorders; EMLA, eutectic mixture of lidocaine and prilocaine; IELT, intra-vaginal ejaculatory latency time; IIEF, International Index of Erectile 
Function; ED, erectile dysfunction; NR, not reported; PC, pre-coitus; PE, premature ejaculation; PEP, Premature Ejaculation Profile; RCT, randomised controlled trial; /d, per 
day. 
Figure 1. PDE5 inhibitors vs. placebo - forest plot of IELT outcomes 
 
PC, pre-coitus 
Figure 2. PDE5 inhibitors vs. SSRIs - forest plot of IELT outcomes 
 
Figure 3. PDE5 inhibitors plus SSRIs vs. SSRIs - forest plot of IELT outcomes 
 
Figure 4. PDE5 inhibitors vs. squeeze technique, lidocaine gel or tramadol - forest plot of IELT 
outcomes 
 
  
Supplementary Figure 1. Study Selection Process - Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) Flow Diagram 
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Additional records 
identified through 
other sources 
(n=0) 
Records screened –  
title and/or abstract 
(n=2,391) 
Records excluded at 
title/abstract stage 
(n=2,369): 
Full-text articles assessed 
for eligibility 
(n=22) 
Full-text articles excluded, 
with reasons (n=7): 
Reviews of PDE5 inhibitors 
(n=5) 
Crossover PDE5 inhibitor 
trials (n=2) 
15 RCTs included in the evidence synthesis 
Supplementary Figure 2. Risk of bias assessment summary by RCT 
 
?, unclear risk of bias; +, low risk of bias, -, high risk of bias 
Supplementary table. Numbers analysed, efficacy outcome results other than IELT, adverse events 
PDE5 inhibitor monotherapy RCTs 
Author Numbers analysed (% of n 
randomised) 
Efficacy outcomes other than IELT Adverse events 
Atan 2006 [21]  Sildenafil, 20 
Sildenafil + topical EMLA, 15 
Topical EMLA, 22 
Placebo, 20 
n analysed NR, assume 100% 
Ejaculation delay 'Improvement' or 'cure': Sildenafil, 
55% (p>0.05); Sildenafil + EMLA, 86%; EMLA, 
77%; Placebo, 40%.  (Not reported if p-value across 
or between-groups) 
 
Headache: Sildenafil, 26%; Flushing: 
Sildenafil, 26% 
Only patients receiving sildenafil 
experienced side effects. 
Aversa 2009[28] Vardenafil, 30 (97%) 
Placebo, 10 (91%) 
Index of Premature Ejaculation (IPE) % increase 
(fold increase): Vardenafil, 114% (2-fold); Placebo, 
% NR, (0-fold). (P-value not reported) 
 
Patients who took vardenafil (vs placebo) reported 
significantly (P<0.01) increased ejaculatory control 
(6±2 vs 16±2), improved overall sexual satisfaction 
(7±2 vs 15±1) and amelioration of distress (4±1 vs 
8±1) scores on the IPE questionnaire. 
The most common adverse events were 
significantly higher with vardenafil 
(p<0.01vs. placebo) after 4 weeks of 
treatment. AEs were headache (10% vs. 
1%), flushing (12% vs. 0%), dyspepsia 
(10% vs. 1%) 
Gameel 2013 [24] Sildenafil + inert gel, 30 (100%) 
Paroxetine + inert gel, 28 (93%) 
Tramadol + inert gel, 29 (97%) 
Lidocaine gel + oral placebo, 30 
(100%) 
Oral placebo + inert gel, 30 (90%) 
Sexual satisfaction (0 to 5 point scale: Mean 
improvement was significantly higher in all active 
treatments vs placebo (p<0.05).   
The greatest improvement was with sildenafil 2.9 (1), 
which was significantly better than paroxetine 
2.2 (0.9) or local anaesthetic 1.9 (0.9) (p < 0.05). 
Greater sleep disturbance, dry mouth, 
nausea, dizziness, fatigue, vomiting, 
sweating, and headache were reported with 
tramadol, sildenafil and paroxetine. All side 
effects were reported as being tolerable. 
Mathers 2009 [15]  Vardenafil, 26 (100%) 
Sertraline, 23 (100%) 
Premature Ejaculation grade (PE Grade) score 
improved in both vardenafil (p<0.01) and sertraline 
(p<0.001) 
Vardenafil: headache (7.1%), face redness 
(7.1%) and nose blockage (2.4%) 
 
Sertraline: lack of appetite (2.4%) and 
nausea (4.8%). 
McMahon 2005[23]  Sildenafil, 73 (94%) 
Placebo, 71 (90%)  
Index of Premature Ejaculation (IPE) 
Sat: Sildenafil, 3.1; placebo, 2.2 
EC: Sildenafil, 1.8; placebo, 1.2 
Conf: Sildenafil, 2.2; placebo, 1.3 
GE: Sildenafil, 48%; placebo, 16% 
Anx: Sildenafil, 48%; placebo, 16% 
(NR if means or medians p-values NR). Patients 
randomized to sildenafil reported significantly (P < 
0.05) higher scores on the IPE for questions assessing 
ejaculatory control (1.8 ± 0.3 vs. 1.3 ± 0.1), 
ejaculatory confidence (2.2 ± 0.2 vs. 1.3 ± 0.1), and 
overall sexual satisfaction (3.1 ± 0.2 vs. 2.2 ± 0.1 
The most common treatment-emergent AEs 
(sildenafil vs. placebo, incidence >3%) 
were headache (15% vs. 1%), flushing 
(15% vs. 0%), dyspepsia (5% vs. 1%), 
abnormal vision (5% vs. 0%), and rhinitis 
(5% vs. 0%). All treatment-emergent AEs 
were considered mild to moderate in 
severity, 
Tang 2004 [18] Sildenafil + behavioural therapy, 30 
Behavioural therapy, 30 
Sertraline + BT, 30 
n analysed NR, assume 100% 
Patient/partner sexual satisfaction (0 to 5 point 
Likert): Sildenafil + BT, 26/30 ‘satisfied’; BT, 19/30 
‘satisfied’ (p=0.04) 
 
None reported in English abstract 
Wang 2007 [16] Sildenafil, 60 
Paroxetine, 60 
Squeeze technique, 60 
n analysed, NR assume 100% 
Premature Ejaculation grade, intercourse satisfactory 
score, frequency of intercourse. P-value for change 
from baseline for all groups reported as 0.000, except 
FI in squeeze group (p=0.20) 
Sildenafil: headache 7 (11.7%), nausea 2 
(3.3%), nasal congestion 5 (8.3%), flushing 
5 (8.3%);  
 
Paroxetine: headache 2 (3.3%) nausea 6 
(10.0), dizziness 2 (3.3), fatigue 3 (5.0%), 
flushing 4 (6.7%) 
PDE5 inhibitor combined with SSRI RCTs 
Author (country) Numbers analysed (% of n 
randomised) 
Efficacy outcomes other than IELT Adverse events 
Culha 2008 [14] Tadalafil + fluoxetine 
Fluoxetine  
Placebo 
Total n, 158 (88%) 
IELT (Visual scale of ejaculatory latency time 
questionnaire [ELTQ]) score increased significantly 
in both study groups compared to placebo. Data o p-
values not reported. 
The authors report that minor side effects 
due to tadalafil and fluoxetine were 
temporary. No data reported. 
Hosseini 2007[25] Sildenafil + fluoxetine, 43 (86%) 
Fluoxetine,48 (96%) 
Intercourse satisfaction (instrument not reported): % 
increase (fold increase): Sildenafil + fluoxetine, 55% 
(3.3-fold); Fluoxetine, 20% (1.2-fold).  
(P-value not reported) 
Sildenafil + fluoxetine: nausea, 8 (18.6%); 
headache, 12 (28%); decreased libido, 2 
(4.7%); flushing, 7 (16.3%) 
 
Fluoxetine: nausea, 7 (14.6%); headache, 6 
(12.5%).  More headache (p<0.05 and 
flushing (p<0.001) with sildenafil. 
Lee 2012[20] Mirodenafil + dapoxetine, 62 (98%) Time from foreplay to beginning intercourse (FTIT) Dapoxetine + mirodenafil - Overall, 28/56 
Dapoxetine + placebo, 56 (98%) Overall sexual act time (OSAT) 
Premature Ejaculation Profile (PEP) 
Significant between-group difference in: 
OSAT week 4, p=0.049; week 8, p=0.026; week 4 to 
8, p=0.040 
 
PEP week12: Perceived control over ejaculation, 
p=0.019; interpersonal difficulty related to 
ejaculation, p=0.013; Index score, p=0.046 
(45.2%); Nausea, 5/56 (8.1%); Diarrhea, 
3/56 (4.8%); Headache, 8/56 (12.9%); 
Dizziness, 6/56 (9.7%); Palpitation, 4/56 
(6.5%); Facial flushing, 2/56 (3.2) 
 
Dapoxetine + placebo - Overall, 18/62 
(32.1%); Nausea, 6/62 (10.7%); Diarrhea, 
2/62 (3.6%); headache, 3/62 (5.4%); 
Dizziness, 5/62 (8.9%); Palpitation, 1/62 
(1.8%); Facial flushing, 1/62 (1.8%) 
 
Mokhtari 2014[26] Tadalafil  + sertraline, 56 
Sertraline, 52 
n analysed NR, assume 100% 
None reported AEs more common with Tad+sert than 
sert+pbo (type and n NR). 5/56 (8.9%) and 
1/52 (1.9%) respectively discontinued 
study. 
Zhang 2005 [19]  Sildenafil + sertraline  
Sertraline 
Total n=72 
n analysed, NR assume 100% 
International Index of Erectile Function (IIEF) 
IS: Sildenafil + sertraline, 13.8; Sertraline, 10.8 
(p<0.001 between groups) 
 
FI: Sertraline + sildenafil, 2.7; Sertraline, 1.9 
(p<0.005 between groups) 
 
Sildenafil + Sertraline had more AEs 
(headache, flushing). (p<0.001) Numbers 
not reported. 
Zhang 2014[17]  Sildenafil +sertraline, 55 (92%) 
Sertraline, 53 (88%) 
PEP measures, and CGIC (subjects reporting at least 
‘better’: 58.2% vs. 35.8%) (P<0.05 for all). 
AEs were reported by 23.3% in the 
sertraline group and 31.7% in the 
combination group. The adverse effects 
included nausea, headache, dizziness, 
flushing, ED, sexual desire difficulties, etc. 
There were no significant differences 
between the two groups.  No withdrawals 
due to AEs or lack of efficacy. 
RCTs evaluating PDE5i alone and in combination with an SSRI 
Author (country) Numbers analysed (% of n 
randomised) 
Efficacy outcomes other than IELT Adverse events 
Mattos 2008[22]  Tadalafil, 15 
Fluoxetine, 15 
Tadalafil + fluoxetine, 15 
Placebo, 15 
n analysed NR, assume 100% 
None reported Tadalafil: headache (3 patients), facial 
redness (2 patients), palpitation (2 patients) 
 
Fluoxetine: yawning and somnolence (3 
patients), asthenia (3 patients), nausea (1 
patient)  
 
Fluoxetine + tadalafil: yawning and 
somnolence (3 patients), nausea (2 patients) 
palpitation (1 patient), muscle soreness (1 
patient) 
Polat 2014[27]  Tadalafil, 50 
Paroxetine, 50 
Tadalafil + paroxetine, 50 
n analysed NR, assume 100% 
International Index of Erectile Function (IIEF) 
questionnaire scores not statistically significant 
(p>0.05). Not reported if between groups or change 
from baseline.  No data. 
Most adverse effects were associated with 
daily paroxetine administration. Fifteen 
patients (30%) in the paroxetine group: 
yawning and somnolence (10/15), asthenia 
(5/15) and nausea (2/15); 12 patients (24%) 
in the tadalafil group: headache (5/12), 
flushing (3/12) and palpitation (4/12); 12 
patients (24%) and  in the paroxetine and 
tadalafil group – nausea (3/12), muscle 
soreness (3/12), palpitation (4/12) and 
flushing (3/12). 
Anx., anxiety; CGIC, Clinical Global Impression of Change; CIPE, Chinese Index of Premature Ejaculation; CMASH, Center for Marital and Sexual Health; conf., 
confidence; def., definition; EMLA, eutectic mixture of lidocaine and prilocaine; IELT, intra-vaginal ejaculatory latency time; IIEF, International Index of Erectile Function; 
IS, intercourse satisfaction; EC, ejaculation control; ED, erectile dysfunction; FI, frequency of intercourse; GE, global efficacy; NR, not reported; PC, pre-coitus; PE, 
premature ejaculation; PEP, Premature Ejaculation Profile; RCT, randomised controlled trial; Sat., satisfaction; SD, standard deviation 
 
 
 
 
 
